OpenAlex
PricingAboutJobs
Log inGet started
Author

Paula Roberts

Observed name: P. Roberts
Observed institutions: University of North Carolina at Chapel Hill, Naval Medical Center Portsmouth, University Health Network, Mayo Clinic, University of Utah, Ottawa Hospital, Huntsman Cancer Institute, Princess Margaret Cancer Centre, Ottawa Hospital Research Institute, Canadian Cancer Trials Group, University of California, Davis
OpenAlex ID: A5015023729
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.
2010 · G. D. Goss, I. Lorimer, et al. · Journal of Clinical Oncology · 76
Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study
2020 · Chris Abbosh, Alexander Frankell, et al. · Cancer Research · 48
Abstract 413: Development of a Highly Customizable Platform for Variant Detection in Circulating Tumor DNA
2019 · Matt Egleston, Paula Roberts, et al. · Clinical Research (Excluding Clinical Trials)
Paraffin-based molecular diagnosis of lung cancer reproduces morphologic and molecular subtypes of lung cancer
2007 · D. N. Hayes, J. Schallheim, et al. · Journal of Clinical Oncology
Works count: 4
Citation count: 124
H-index: 2
I10-index: 2
Year
Topic
Type
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms